Lilly's incretin franchises continue to drive top-line growth as the company also expands into neurosciences and defends its obesity marketing against Novo Nord

A head-to-head win for Lilly's next-generation incretin strengthens its position in the escalating obesity and diabetes competition with Novo Nordisk.

The revised maximum retail prices, effective November 9, lower costs for many oncology brands while leaving expensive innovator medicines untouched.

The ruling lets Lilly continue comparative advertising for its obesity drugs, extending the legal fight between the two GLP-1 leaders.

Korea's first domestically developed obesity treatment enters a three-way market race with Novo's Wegovy and Lilly's Mounjaro, competing partly on price.

Experts argue the magnitude of the NPPA reductions highlights how far above cost some oncology medicines were priced in India.

Justices questioned whether drugmakers can be left to set prices freely and were urged to form an expert panel on gaps in cancer drug price controls.

Lilly is investing in neuroscience programs as it looks to build a second growth pillar beyond its incretin drugs.

Multinational drugmakers are deepening China ties across development and manufacturing, boosting the local industry's scale.

Both parties are expected to keep pressure on drug pricing and policy regardless of midterm outcomes.

A shift in Congress could reopen oversight of the administration's pricing agreements with Novo Nordisk.

Most-favored-nation pricing policy carries potential knock-on effects for European drug launches and access.

The biotech disclosed quarterly results alongside a rare-disease designation for its pancreatic cancer drug.

The company can begin clinical testing of an inhaled therapy for pulmonary arterial hypertension.

The timing of the purchase ahead of an FDA decision raises conflict-of-interest questions.

The Korean pension fund's reallocation signals changing institutional appetite within the country's healthcare and consumer-health sectors.

The designation gives the company's drug a potential seven-year market exclusivity window upon approval.

Supplements, body contouring and drug development are all evolving around the expanding demand created by incretin therapies.